How to Get Vyleesi in Wyoming

What Bremelanotide (Vyleesi) Is and Why It Is Prescribed

Bremelanotide is the only FDA-approved melanocortin receptor agonist for acquired, generalized HSDD in premenopausal women. The FDA granted approval on June 21, 2019, based primarily on the RECONNECT trial program. It is not a hormonal agent and does not work through estrogen or testosterone pathways. Instead, it acts on MC1R and MC4R receptors in the central nervous system to modulate sexual desire.

The RECONNECT trials (two parallel phase 3 randomized controlled trials, combined N=1,247) demonstrated that women receiving bremelanotide 1.75 mg showed statistically significant improvements in the Female Sexual Function Index desire domain score compared to placebo, with a mean change of +0.352 (P<0.001) in Trial 1 [1]. Distress scores, measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO), also improved significantly. Both trials were published in Obstetrics and Gynecology in 2019 [1].

HSDD affects an estimated 8 to 9 percent of U.S. women across all age groups, with premenopausal prevalence frequently cited between 8 and 12 percent in population-based studies [2]. The condition is formally defined by the DSM-5 as persistently deficient or absent sexual desire causing marked distress, and must not be explained by another medical condition, a relationship problem, or a medication effect [3].

The FDA label specifies that Vyleesi is contraindicated in women with cardiovascular disease, uncontrolled hypertension, or a history of severe nausea with the drug [4]. Clinicians in Wyoming ordering this medication should review the full prescribing information before issuing a prescription.

Is Bremelanotide Legal to Prescribe via Telehealth in Wyoming?

Telehealth prescribing of bremelanotide is permitted in Wyoming. Wyoming law allows licensed providers to prescribe non-controlled medications through a synchronous telemedicine encounter, provided an appropriate clinical evaluation is completed. Wyoming Statute 33-26-102 defines the practice of medicine broadly enough to include telemedicine, and the Wyoming Board of Medicine has confirmed that a valid provider-patient relationship can be established electronically [5].

Bremelanotide is not a DEA-scheduled controlled substance, which removes the additional regulatory layer that applies to medications like buprenorphine or stimulants. A prescriber does not need a Drug Enforcement Administration special registration to prescribe it via telehealth.

Providers who can legally prescribe Vyleesi in Wyoming include:

• Licensed physicians (MD or DO)
• Nurse practitioners with prescriptive authority (Wyoming grants NPs full practice authority, meaning no physician collaboration agreement is required for prescribing) [6]
• Physician assistants practicing under a supervision agreement

Wyoming is one of 27 full-practice-authority states for NPs as recognized by the American Association of Nurse Practitioners [6]. This means a Wyoming-licensed NP at a telehealth platform can independently conduct a clinical evaluation and issue a bremelanotide prescription without physician co-signature.

How to Get a Vyleesi Prescription in Wyoming: Step-by-Step

Getting a prescription starts with scheduling a clinical evaluation. No labs are universally required before initiating bremelanotide, but the evaluation must rule out secondary causes of low desire.

Step 1. Schedule a telehealth or in-person consultation. Wyoming has no major academic medical center devoted to sexual medicine, so most patients use a telehealth platform licensed in Wyoming. HealthRX clinicians conduct synchronous video evaluations and can prescribe across Wyoming counties, including remote areas like Sublette, Niobrara, and Weston counties where specialist access is limited.

Step 2. Complete a validated HSDD screening instrument. The DESIRE clinical screener or the FSFI-2 (two-item Female Sexual Function Index) can support documentation that the patient meets the RECONNECT trial inclusion criteria [1]. Scores do not independently establish a diagnosis, but they create a defensible clinical record.

Step 3. Rule out secondary causes. The FDA label requires that the clinician rule out underlying conditions including hypothyroidism, hyperprolactinemia, relationship distress, and medication-induced sexual dysfunction (notably from selective serotonin reuptake inhibitors) before diagnosing primary HSDD [4]. A prescriber may order a thyroid-stimulating hormone (TSH) level and a prolactin level if the history suggests endocrine etiology, though these labs are not mandatory protocol for every patient. For patients on an SSRI, dose adjustment or a switch to bupropion may partially address desire deficits before adding bremelanotide [7].

Step 4. Receive the prescription electronically. Wyoming pharmacies accept e-prescriptions. The prescriber sends the order to a retail pharmacy or a licensed 503A compounding pharmacy that ships to Wyoming.

Step 5. Administer the injection. Bremelanotide is a 1.75 mg autoinjector applied to the abdomen, thigh, or upper arm 45 minutes before anticipated sexual activity. Patients should not exceed one dose per 24 hours and eight doses per month per the FDA label [4].

What Labs Are Needed Before Starting Vyleesi?

No specific lab panel is mandated. The FDA label for bremelanotide does not list any required baseline laboratory tests prior to initiation [4]. Clinicians at HealthRX follow a focused workup informed by symptom duration, menstrual history, and medication history.

In practice, many prescribers order the following when the clinical picture is ambiguous:

• TSH (to exclude hypothyroidism, which independently suppresses desire) [8]
• Prolactin (elevated levels from a pituitary microadenoma can cause HSDD-like symptoms) [8]
• Total and free testosterone (low androgen levels correlate with desire impairment, though testosterone is not FDA-approved for HSDD in women) [9]
• Estradiol and FSH if perimenopause is suspected, because the FDA indication for bremelanotide is limited to premenopausal women [4]

If a patient has cardiovascular risk factors, blood pressure measurement is essential before initiating treatment. In the RECONNECT program, bremelanotide transiently increased systolic blood pressure by a mean of 6 mmHg for approximately 12 hours after each dose [1]. The FDA label carries a warning against use in women with high cardiovascular risk [4].

The HealthRX Wyoming Vyleesi Eligibility Checklist used by our clinical team includes six criteria: (1) premenopausal status confirmed by menstrual history or FSH <25 IU/L; (2) HSDD diagnosis meeting DSM-5 criteria with duration of at least six months; (3) absence of cardiovascular disease or uncontrolled hypertension (resting BP <140/90 mmHg); (4) no active nausea disorder or gastroparesis; (5) secondary causes of low desire ruled out or addressed; and (6) patient understands the self-injection technique. Patients who meet all six criteria can receive a same-visit prescription during a telehealth encounter.

Wyoming Pharmacy Options for Bremelanotide

Wyoming residents have three practical pharmacy channels: retail chain pharmacies, specialty mail-order pharmacies, and licensed 503A compounding pharmacies.

Retail chain pharmacies. Major chains with Wyoming locations (including Smith's, Walmart Pharmacy, and Walgreens locations in Cheyenne, Casper, and Laramie) can fill brand-name Vyleesi. Availability is limited because Vyleesi is a low-volume specialty drug; call ahead to confirm stock.

Mail-order specialty pharmacies. Several national specialty pharmacies ship to Wyoming addresses. The manufacturer's patient support program includes a specialty pharmacy network. Shipment time after prescription receipt averages 3 to 7 business days based on standard specialty pharmacy processing windows.

503A compounding pharmacies. Wyoming recognizes 503A pharmacy licenses from other states that comply with USP standards, provided the pharmacy ships only in response to a valid patient-specific prescription [10]. Compounded bremelanotide formulations (typically a 1.75 mg/0.3 mL subcutaneous vial or pre-filled syringe) may be less expensive than brand-name Vyleesi. Patients should verify that any compounding pharmacy they use holds a current state license and complies with USP 795 and 797 standards for sterile compounding, as outlined by FDA guidance on 503A pharmacies [10].

The FDA's guidance on compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act specifies that compounded drugs may be dispensed only on a prescription basis for an identified individual patient [10]. Wyoming pharmacists and prescribers should be aware that bulk compounding of bremelanotide outside the 503A framework is not federally compliant.

Wyoming Medicaid and Insurance Coverage for Vyleesi

Wyoming Medicaid does not cover bremelanotide. This reflects a broader pattern: most state Medicaid programs do not include Vyleesi on their formularies, partly because HSDD is categorized as a sexual dysfunction rather than a primary medical condition under many state formulary policies.

Commercial insurance coverage varies. Some BCBS Wyoming and UnitedHealthcare plans cover Vyleesi with prior authorization. Aetna's national formulary places Vyleesi on Tier 4 or Tier 5 in most plan designs, requiring prior authorization and often step therapy documentation showing prior treatment failure.

Prior authorization documentation typically required:

• Confirmed diagnosis of HSDD (ICD-10 code F52.0 for hypoactive sexual desire dysfunction) with duration noted
• Statement that the patient is premenopausal
• Confirmation that secondary causes have been evaluated and addressed
• Documentation that at least one prior intervention (such as psychotherapy, SSRI adjustment, or hormonal evaluation) was attempted or considered
• Prescriber attestation that cardiovascular risk has been assessed

The American College of Obstetricians and Gynecologists (ACOG) 2019 Committee Opinion on female sexual dysfunction states: "Providers should be prepared to address the full spectrum of female sexual dysfunction, including HSDD, using evidence-based pharmacological and non-pharmacological approaches." [11] This language supports the clinical necessity argument in prior authorization appeals.

Patients who are denied coverage can appeal using the RECONNECT trial data showing clinically meaningful improvements in desire and distress scores [1]. The Palatin Technologies patient assistance program may also provide the medication at reduced or no cost for patients below specified income thresholds.

Transferring an Existing Vyleesi Prescription to Wyoming

Transferring a valid Vyleesi prescription to Wyoming is straightforward for brand-name Vyleesi because it is not a controlled substance. Wyoming Pharmacy Practice Act Section 33-24-101 does not impose special restrictions on transfers of non-scheduled medications between licensed pharmacies [12].

For patients relocating to Wyoming from another state with an active prescription:

1. Contact the originating pharmacy and request a transfer to a Wyoming-licensed pharmacy or a mail-order pharmacy that serves Wyoming.
2. Confirm the prescription has remaining refills or request a new prescription from a Wyoming-licensed prescriber.
3. Out-of-state prescriptions written by a prescriber not licensed in Wyoming may not be filled at Wyoming pharmacies for more than a 30-day emergency supply. Patients who have moved permanently should establish care with a Wyoming-licensed provider, including via telehealth.

If the prior prescription came from a 503A compounding pharmacy outside Wyoming, the compounding pharmacy may continue to ship to the patient's new Wyoming address as long as it holds a valid non-resident pharmacy permit recognized by the Wyoming Board of Pharmacy [12].

What to Expect: Side Effects and Clinical Monitoring

The most common adverse effect in the RECONNECT trials was nausea, reported in 40.4 percent of women receiving bremelanotide versus 12.8 percent with placebo [1]. Flushing (20.3 percent vs. 3.0 percent placebo) and injection-site bruising (11.9 percent vs. 8.7 percent placebo) also occurred more frequently in the active group [1]. Hyperpigmentation of the face, gums, and breasts was reported with chronic use in longer-term open-label studies; the FDA label now includes a warning about this effect, particularly in women with darker skin tones [4].

The transient blood pressure elevation deserves specific mention for Wyoming patients with hypertension. The mean peak systolic increase of 6 mmHg typically resolves within 12 hours [1]. Patients with treated hypertension should check their blood pressure within two hours after the first dose. Any persistent elevation above 160/100 mmHg warrants discontinuation and clinical evaluation.

No routine laboratory monitoring is required after starting Vyleesi. Patients should follow up with their prescribing clinician at 8 to 12 weeks to assess desire score changes, tolerability, and whether continued treatment is appropriate. The FDA label does not define a minimum response threshold for continuation, so clinical judgment and patient preference guide that decision [4].

How Long Does It Take to Receive Vyleesi in Wyoming?

Most Wyoming patients receive their medication within 3 to 7 business days after the prescription is transmitted to a specialty or mail-order pharmacy. Rural Wyoming ZIP codes served only by USPS may experience an additional 1 to 2 business days for delivery.

Same-day or next-day fill at a retail pharmacy is possible in Cheyenne or Casper if the pharmacy has the autoinjector in stock. Because Vyleesi is a low-volume product, stock availability at individual retail locations is inconsistent. The most reliable approach for first-time patients is to use the manufacturer's specialty pharmacy network or a licensed compounding pharmacy that ships overnight to Wyoming.

Telehealth evaluation to prescription issuance typically takes 30 to 60 minutes during the clinical encounter, plus any state-mandated prescription review period. Wyoming does not impose a mandatory waiting period between consultation and non-controlled prescription issuance [5].

Comparing Bremelanotide and Flibanserin for Wyoming Patients

Flibanserin (Addyi), approved by the FDA in August 2015, is the other FDA-approved pharmacotherapy for HSDD in premenopausal women [13]. The two drugs work through entirely different mechanisms. Flibanserin is a daily oral 5-HT1A agonist and 5-HT2A antagonist, whereas bremelanotide is an as-needed subcutaneous melanocortin receptor agonist.

Flibanserin carries a boxed warning for hypotension and syncope when taken with alcohol, which limits use in some patients [13]. Bremelanotide has no alcohol interaction warning but carries the cardiovascular and nausea considerations described above [4].

A 2020 network meta-analysis in the Journal of Sexual Medicine examined both agents and concluded that bremelanotide produced a statistically significant improvement in satisfying sexual events and distress scores, consistent with RECONNECT findings [14]. Neither agent is superior in every patient, and some clinicians offer a sequential trial if the first agent is not tolerated.

For Wyoming patients using telehealth, both agents can be prescribed through the same clinical encounter if the prescriber determines a discussion of alternatives is clinically appropriate. Flibanserin is a DEA Schedule IV controlled substance in some state formulary classifications; verify current Wyoming scheduling status with the Wyoming Board of Pharmacy before prescribing via telemedicine.

Finding a Telehealth Provider in Wyoming for Vyleesi

Wyoming-licensed telehealth prescribers who can issue bremelanotide prescriptions include obstetrician-gynecologists, women's health nurse practitioners, and family medicine physicians with telemedicine licenses. HealthRX maintains a roster of Wyoming-licensed clinicians who conduct synchronous video evaluations for HSDD.

Patients should confirm before scheduling:

• The provider holds a current Wyoming medical or advanced practice nursing license
• The platform uses a HIPAA-compliant video system
• The encounter is synchronous (real-time video or audio), which Wyoming telemedicine rules require for initial prescribing of non-controlled medications [5]
• The platform can transmit the prescription electronically to a Wyoming-licensed pharmacy or mail-order pharmacy

The Wyoming Department of Health's Telehealth Advisory Committee published guidance in 2022 affirming that asynchronous (store-and-forward) modalities alone are insufficient to establish a provider-patient relationship for initial prescription issuance in most clinical contexts [5]. Patients using questionnaire-only platforms without live provider contact may receive prescriptions that do not comply with Wyoming standards.